The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results.
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - 4D Pharma; Ipsen; Janssen; Novartis; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; BIOCAD; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca; Bristol-Myers Squibb
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Toshihiko Doi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Rakuten Medical Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; KYOWA KIRIN; MSD; Otsuka; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Dirk Arnold
Employment - Asklepios Kliniken
Honoraria - Amgen; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Ipsen; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Roche/Genentech; SERVIER
Consulting or Advisory Role - AstraZeneca; Bayer; Biocompatibles; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Terumo
Research Funding - Oncolytics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - ESMO; ESMO Open; European Organisation for Research and Treatment of Cancer (EORTC); German Cancer Society; German Society for Hematology and Medical Oncology
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Bayer; Roche; Sanofi
Consulting or Advisory Role - Biocartis; cureteq
 
Gunnar Folprecht
Honoraria - Bristol-Myers Squibb; Falk Foundation; Merck KGaA; Merck Sharp & Dohme; Roche/Genentech; Sanofi/Aventis; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exact Sciences; Incyte; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche/Genentech; SERVIER
Research Funding - Merck KGaA
 
Helen Winter
No Relationships to Disclose
 
Rasha Cosman
No Relationships to Disclose
 
Graziela Zibetti Dal Molin
No Relationships to Disclose
 
Qi Xia
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Saltanat Najmi
Employment - Johnson & Johnson; Tmunity Therapeutics, Inc.
Stock and Other Ownership Interests - Johnson & Johnson
 
Constance Hammond
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development; Pfizer
 
Shibu Thomas
Employment - Janssen
Leadership - Janssen
Stock and Other Ownership Interests - Janssen
Honoraria - Janssen
Patents, Royalties, Other Intellectual Property - Janssen
Travel, Accommodations, Expenses - Janssen
 
Spyros Triantos
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Hussein Sweiti
Employment - Janssen Research & Development
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen